Associated Papers
Trans-activating mutations of the pseudokinase ERBB3.
Koivu MKA et al.
Oncogene, 2024
38806620 (PubMed )
Supplement: 41388_2024_3070_MOESM2_ESM.xlsx › Excel_for_Processed_NGS_data
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
37248814 (PubMed )
Supplement: supplement_1.xlsx › Supp._Table_5
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A et al.
Targeted Oncology, 2022
Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Squamous Cell Carcinomas Identifies KMT2C as a Potential Tumor Suppressor.
Machnicki MM et al.
Frontiers in Oncology, 2022
35664801 (PubMed )
Supplement: Table_3.xlsx › S3.4-FaDu_mutation_summary
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Conlon NT et al.
British Journal of Cancer, 2021
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Hyman DM et al.
Nature, 2018
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Jordan EJ et al.
Cancer Discovery, 2017
Select a paper to view details